Here are relevant reports on : genomic-diagnostics-market
-
Cancer Profiling Market by Technology (Immunoassay, NGS, PCR), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Biomarker Discovery, Diagnostics, Prognostics) - Global Forecast to 2027
The global cancer profiling market in terms of revenue was estimated to be worth $9.7 billion in 2022 and is poised to reach $16.0 billion by 2027, growing at a CAGR of 10.6% from 2022 to 2027. The growth in this market is driven by rising funding investments in cancer research and technological advancements in profiling technologies. In addition, the growing need for point-of-care diagnostics is expected to offer significant growth opportunities for market players. On the other hand, a low biomarker discovery-to-approval ratio and a poor regulatory and reimbursement scenario challenge the growth of the cancer profiling market.
- Published: November 2022
- Price: $ 4950
- TOC Available:
-
North America Nucleic Acid Isolation and Purification Market by Product (Kits, Reagents, Instruments), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA), Application (Diagnostics, Personalized Medicine), End User (CROs) - Forecast to 2030
The North America Nucleic Acid Isolation and Purification Market, valued at USD 2.80 billion in 2024, stood at USD 2.98 billion in 2025 and is projected to advance at a resilient CAGR of 9.3% from 2025 to 2030, culminating in a forecasted valuation of USD 4.64 billion by the end of the period. The growth of the North America nucleic acid isolation and purification market is largely dependent on the region's substantial number of molecular tests and quick acceptance of NGS-based workflows.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Europe Nucleic Acid Isolation and Purification Market by Product (Kits, Reagents, Instruments), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA, mRNA), Application (Diagnostics, Personalized Medicine), End User (CROs) - Forecast to 2030
The Europe nucleic acid isolation and purification market, valued at US$1.52 billion in 2024, stood at US$1.61 billion in 2025 and is projected to advance at a resilient CAGR of 8.4% from 2025 to 2030, culminating in a forecasted valuation of US$2.41 billion by the end of the period. The growth of the Europe nucleic acid isolation and purification market is strongly linked to the region’s high volume of molecular tests and the steady adoption of PCR- and NGS-based workflows.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Asia Pacific Nucleic Acid Isolation and Purification Market by Product (Kits, Reagents, Instruments), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA), Application (Diagnostics, Personalized Medicine), & End User (CROs) - Forecast to 2030
The Asia Pacific nucleic acid isolation and purification market, valued at US$1.49 billion in 2024, stood at US$1.61 billion in 2025 and is projected to advance at a resilient CAGR of 10.5% from 2025 to 2030, culminating in a forecasted valuation of US$2.65 billion by the end of the period. The Asia Pacific market for nucleic acid isolation and purification is expanding due to the increasing number of molecular tests and the scale-up of PCR and NGS across the region.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Nucleic Acid Isolation and Purification Market by Product (Kits, Reagents, Instruments), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA), Application (Diagnostics, Personalized Medicine), End User (CROs), Region - Global Forecast to 2030
The global nucleic acid isolation and purification market, valued at US$6.67 billion in 2024, stood at US$7.10 billion in 2025 and is projected to advance at a resilient CAGR of 9.1% from 2025 to 2030, culminating in a forecasted valuation of US$10.99 billion by the end of the period. The global market for nucleic acid isolation and purification (NAIP) is expanding largely due to the increased use of PCR and NGS in clinical diagnostics and research. Laboratories globally require DNA/RNA of high purity and free of inhibitors in order to carry out reliable workflows for sequencing, oncology panels and routine molecular testing.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Europe Artificial Intelligence (AI) in Healthcare Market by Offering (Integrated), Function (Diagnosis, Genomic, Precision Medicine, Radiation, Telehealth, RPM, Immunotherapy, Supply Chain), Application (Clinical), End User (Hospitals) - Forecast to 2030
The Europe Artificial Intelligence (AI) in Healthcare Market, valued at USD 4.20 billion in 2024, stood at USD 6.12 billion in 2025 and is projected to advance at a resilient CAGR of 39.0% from 2025 to 2030, culminating in a forecasted valuation of USD 31.72 billion by the end of the period. This growth is driven by strong regulatory support for digital transformation and the rising adoption of AI-enabled clinical workflows across European health systems.
- Published: December 2025
- Price: $ 4950
- TOC Available:
-
US Artificial Intelligence (AI) in Healthcare Market by Offering (Integrated), Function (Diagnosis, Genomic, Precision Medicine, Radiation, Telehealth, Immunotherapy, Pharmacy, Supply Chain), Application (Clinical), End User (Hospitals) - Forecast to 2030
The US artificial intelligence (AI) in healthcare market, valued at US$5.98 billion in 2024, stood at US$8.65 billion in 2025 and is projected to advance at a resilient CAGR of 38.0% from 2025 to 2030, culminating in a forecasted valuation of US$43.30 billion by the end of the period. Market growth is driven by rising demand from providers for automation, nationwide labor shortages, increasing clinical complexity, and strong investment in predictive analytics, imaging AI, and GenAI.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Molecular Breeding Market by Process (QTL Mapping, Marker-Assisted Selection, Marker-Assisted Backcrossing, and Genomic Selection), Marker (SNP, SSR), Application (Crop Breeding and Livestock Breeding), and Region-Global Forecast to 2023
The molecular breeding market is estimated at USD 1.79 billion in 2018 and is projected to reach USD 3.95 billion by 2023, at a CAGR of 17.11% during the forecast period. The agricultural benefits associated with these adjuvant solutions are the major factors contributing to the growth of this market, globally. The growth of economies in developing countries, coupled with the increasing R&D expenses in the agriculture industry drives the growth potential of these markets.The global market for molecular breeding is dominated by key players such as Eurofins (Luxembourg), Illumina (US), LGC Limited (UK), Thermo Fisher Scientific (US), and SGS (Switzerland). Some emerging players in the molecular breeding market include DanBred (Denmark), Intertek Group (UK), LemnaTec (Germany), Charles River (US), Slipstream Automation (New Zealand), and Fruitbreedomics (consortium).
- Published: September 2018
- Price: $ 4950
- TOC Available:
-
Molecular Cytogenetics Market by Product (Kits, Reagents, Probes, Instrument, Software, Services), Technique (FISH, CISH, Comparative Genomic Hybridization [Array-based, Standard]), Application (Cancer, Personalized Medicine) - Global Forecast to 2030
The global molecular cytogenetics market, valued at US$0.97 billion in 2024, stood at US$1.02 billion in 2025 and is projected to advance at a resilient CAGR of 7.1% from 2024 to 2030, culminating in a forecasted valuation of US$1.43 billion by the end of the period. The market growth is fueled by increasing incidence of cancer & genetic disorders and rising usage of molecular cytogenetics in clinical pathology testing.
- Published: October 2025
- Price: $ 4950
- TOC Available:
-
Genomic Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Technology (NGS, PCR), Disease (Cancer, Infectious) -Forecast to 2030
The global genomic biomarkers market, valued at US$26.78 billion in 2024, stood at US$29.00 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2024 to 2030, culminating in a forecasted valuation of US$50.31 billion by the end of the period. Genomic biomarkers are measurable features of DNA and RNA used to aid disease diagnosis, characterize disease states, and guide therapeutic decision-making.
- Published: January 2026
- Price: $ 4950
- TOC Available:
Records 1 to 10 of 50
